April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
2 citations
,
December 2019 in “Chinese medical journal/Chinese Medical Journal” A woman with a scalp infection and herpes recovered fully after treatment.
1 citations
,
May 2025 in “Cytotechnology”
April 2018 in “Journal of Investigative Dermatology” Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
25 citations
,
June 2015 in “Acta dermato-venereologica” Methotrexate can help some kids with severe hair loss regrow hair.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
March 2026 in “Revista Ibero-Americana de Humanidades, Ciências e Educação” Using dutasteride during hair transplants improves results and reduces hair loss.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
January 2007 in “Journal of Clinical Dermatology” The topical solution increased hair count but wasn't significantly better than placebo in other measures.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
5-ARI therapy may help prevent prostate cancer progression.
11 citations
,
November 2019 in “Journal of the American Academy of Dermatology” Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
March 2026 in “Journal of Personalized Medicine” Genetic differences affect breast cancer treatment success with tamoxifen in South African patients.
February 2023 in “Materials today bio” The treatment effectively promotes hair regrowth in androgenetic alopecia without causing skin irritation.
70 citations
,
April 2011 in “British journal of dermatology/British journal of dermatology, Supplement” Methotrexate sometimes helps regrow hair in children with severe alopecia areata and is generally safe.
September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.
2 citations
,
March 2013 in “Phytotherapy Research” Ascorbigen increases hair cell growth in a lab setting but does not prevent hair loss from chemotherapy in mice.
2 citations
,
October 2020 in “Journal of Investigative Dermatology Symposium Proceedings” The botanical treatment for hair loss shows promise, especially for children.
November 2008 in “Cancer Prevention Research” Chemoprevention can significantly lower cancer risks and needs more research and collaboration.
5 citations
,
February 2016 in “International Journal of Cancer” Topical vasoconstrictors do not reduce chemotherapy effectiveness against leukemia in mice.
January 2026 in “BULLETIN OF STOMATOLOGY AND MAXILLOFACIAL SURGERY” Both treatments help hair regrowth, but Botulinum Toxin-A has fewer side effects.
January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.